PL3568149T3 - Kompozycja farmaceutyczna do zapobiegania zapaleniu wątroby, zwłóknieniu wątroby i marskości wątroby lub leczenia takich chorób zawierająca białka fuzyjne - Google Patents

Kompozycja farmaceutyczna do zapobiegania zapaleniu wątroby, zwłóknieniu wątroby i marskości wątroby lub leczenia takich chorób zawierająca białka fuzyjne

Info

Publication number
PL3568149T3
PL3568149T3 PL17870009.2T PL17870009T PL3568149T3 PL 3568149 T3 PL3568149 T3 PL 3568149T3 PL 17870009 T PL17870009 T PL 17870009T PL 3568149 T3 PL3568149 T3 PL 3568149T3
Authority
PL
Poland
Prior art keywords
liver
hepatitis
preventing
treatment
pharmaceutical composition
Prior art date
Application number
PL17870009.2T
Other languages
English (en)
Inventor
Han Na Hong
Jun Hwan Kim
Hyun Ho Choi
Dohoon Kim
Taewang Kim
Se Woong Oh
Moo Young Song
Jong Gyun Kim
Original Assignee
Yuhan Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corporation filed Critical Yuhan Corporation
Publication of PL3568149T3 publication Critical patent/PL3568149T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL17870009.2T 2016-11-10 2017-11-10 Kompozycja farmaceutyczna do zapobiegania zapaleniu wątroby, zwłóknieniu wątroby i marskości wątroby lub leczenia takich chorób zawierająca białka fuzyjne PL3568149T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160149866 2016-11-10
PCT/KR2017/012726 WO2018088838A1 (en) 2016-11-10 2017-11-10 Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins

Publications (1)

Publication Number Publication Date
PL3568149T3 true PL3568149T3 (pl) 2025-07-07

Family

ID=62110477

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17870009.2T PL3568149T3 (pl) 2016-11-10 2017-11-10 Kompozycja farmaceutyczna do zapobiegania zapaleniu wątroby, zwłóknieniu wątroby i marskości wątroby lub leczenia takich chorób zawierająca białka fuzyjne

Country Status (15)

Country Link
US (1) US11179440B2 (pl)
EP (1) EP3568149B1 (pl)
JP (3) JP7328891B2 (pl)
KR (1) KR102692516B1 (pl)
CN (1) CN110121355B (pl)
AU (2) AU2017358289C1 (pl)
BR (1) BR112019009581A2 (pl)
CA (1) CA3042512A1 (pl)
ES (1) ES3023833T3 (pl)
HU (1) HUE071618T2 (pl)
MX (1) MX2019005380A (pl)
NZ (1) NZ752661A (pl)
PL (1) PL3568149T3 (pl)
WO (1) WO2018088838A1 (pl)
ZA (1) ZA201903306B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US11560416B2 (en) 2017-04-21 2023-01-24 Yuhan Corporation Method for producing dual function proteins and its derivatives
EP3810183A1 (en) * 2018-06-21 2021-04-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
US20230265152A1 (en) * 2020-07-02 2023-08-24 Sanofi Glp-1r agonist / fgf21 fusion proteins
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
WO2025058417A1 (ko) * 2023-09-11 2025-03-20 서울대학교병원 안지오포이에틴-1 융합 단백질 및 이의 용도
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
WO1990002175A1 (en) 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
AU2002322394A1 (en) 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
JP2007531715A (ja) 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合ｆｇｆ−２１化合物
JP2006094727A (ja) * 2004-09-28 2006-04-13 Masaki Kamakura 細胞増殖促進作用及び器官再生促進作用を有すポリペプチドをコードする遺伝子
WO2008102923A1 (en) 2007-02-23 2008-08-28 Sk Chemicals Co., Ltd. Process for producing and purifying factor viii and its derivatives
WO2009020802A2 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CN101732715B (zh) * 2008-11-07 2012-02-15 中国人民解放军军事医学科学院放射与辐射医学研究所 LSECtin及其融合蛋白在制备抑制癌细胞向肝转移药物中的应用
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
PT3248610T (pt) 2009-05-05 2024-02-01 Amgen Inc Mutantes fgf21 e suas utilizações
MX2011011815A (es) * 2009-05-05 2012-01-27 Amgen Inc Mutantes fgf21 y usos de los mismos.
WO2010142665A1 (en) 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
ES2543634T3 (es) 2010-01-22 2015-08-20 Novo Nordisk A/S Proceso para preparación de FGF-21 con grado de O-glicosilación bajo
US9655974B2 (en) 2010-07-20 2017-05-23 Novo Nordisk A/S N-terminal modified FGF21 compounds
CN102370686B (zh) * 2010-08-26 2013-09-18 上海中医药大学附属曙光医院 治疗慢性肝病的药物组合物及其应用
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
MX2014002260A (es) 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
CN102558358A (zh) * 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
CN103860565B (zh) * 2012-12-10 2017-05-17 中国人民解放军军事医学科学院毒物药物研究所 一种治疗肝纤维化的药物组合物
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
WO2016048995A2 (en) * 2014-09-23 2016-03-31 Salk Institute For Biological Studies Fgf19 truncations and mutants and uses thereof
CN107108710B (zh) * 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
CN105288592A (zh) * 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用
CN108570109B (zh) * 2017-03-14 2022-04-26 广东东阳光药业有限公司 包含免疫球蛋白Fc部分的双靶点融合蛋白
US11560416B2 (en) * 2017-04-21 2023-01-24 Yuhan Corporation Method for producing dual function proteins and its derivatives

Also Published As

Publication number Publication date
AU2017358289A1 (en) 2019-06-20
US11179440B2 (en) 2021-11-23
JP7328891B2 (ja) 2023-08-17
US20190314452A1 (en) 2019-10-17
CN110121355B (zh) 2023-09-12
WO2018088838A1 (en) 2018-05-17
EP3568149A4 (en) 2020-07-22
JP2023002571A (ja) 2023-01-10
ZA201903306B (en) 2020-09-30
BR112019009581A2 (pt) 2019-10-08
JP2020502053A (ja) 2020-01-23
ES3023833T3 (en) 2025-06-03
AU2017358289C1 (en) 2025-05-08
AU2025201790A1 (en) 2025-04-03
KR20180052545A (ko) 2018-05-18
NZ752661A (en) 2025-10-31
HUE071618T2 (hu) 2025-09-28
KR102692516B1 (ko) 2024-08-08
AU2017358289B2 (en) 2024-12-19
CA3042512A1 (en) 2018-05-17
RU2019117767A3 (pl) 2021-01-28
CN110121355A (zh) 2019-08-13
MX2019005380A (es) 2019-08-12
RU2019117767A (ru) 2020-12-10
EP3568149A1 (en) 2019-11-20
EP3568149B1 (en) 2025-03-12
JP2025114622A (ja) 2025-08-05
EP3568149C0 (en) 2025-03-12

Similar Documents

Publication Publication Date Title
PL3568149T3 (pl) Kompozycja farmaceutyczna do zapobiegania zapaleniu wątroby, zwłóknieniu wątroby i marskości wątroby lub leczenia takich chorób zawierająca białka fuzyjne
IL282372A (en) Haploid induction compositions and methods for use therefor
IL270714A (en) Liver organoid compositions and methods of making and using same
EP3360554A4 (en) AGGREGATE AGAINST HEPATITIS B VIRUS
DK3368554T3 (da) Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme
EP3551212A4 (en) NEW RECOMBINATED KLOTHO PROTEINS AND COMPOSITIONS AND METHODS INCLUDING THEM
GB201720163D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B
EP3474857C0 (en) COMPOSITIONS AND METHODS FOR RELEASING THERAPEUTIC AGENTS
EP3433269C0 (en) PD-1 AND 4-1 BB FUSION PROTEINS
EP3548497A4 (en) SEPIAPTERIN POLYMORPHS AND THEIR SALTS
DK3381451T3 (da) Farmaceutisk sammensætning brugt til at reducere lokaliseret fedt samt brug af den farmaceutiske sammensætning
IL253538B (en) Heterocyclic compound and pharmaceutical compound containing it
DK3247352T3 (da) Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion
EP3305802A4 (en) NOVEL PEPTIDE AND COMPOSITION THEREOF
KR20180084995A (ko) Fmdv 및 e2 융합 단백질 및 이의 용도
EP3562475A4 (en) THIN FILM FORMULATIONS OF 4-DIPHENYLMETHYL-1-PIPERAZINE DERIVATIVES AND THEIR SALTS
PH12017500320A1 (en) Pharmaceutical composition comprising gold-containing agent for preventing or treating liver fibrosis or liver cirrhosis
IL265292A (en) Medicinal compound and method for treating non-alcoholic fatty liver disease
DK3506923T3 (da) Farmaceutisk sammensætning til behandling af pædiatrisk væksthormonmangel indeholdende hgh-fusionsprotein
DK3399040T3 (da) Fremgangsmåde til fremstilling af porcine circovirus type 2 capsid-protein og farmaceutisk sammensætning omfattende samme
DK3404033T3 (da) C-glukosidderivat med kondenseret phenylring eller farmaceutisk acceptabelt salt deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende dette
PT3503885T (pt) Composição farmacêutica e métodos de utilização
DK3842436T3 (da) Farmaceutisk sammensætning omfattende imidazopyridin- eller imidazotriazinderivater til anvendelse i behandlingen af skizofreni
DK3416677T3 (da) Farmaceutisk sammensætning omfattende rekombinant hgh til behandlingen af væksthormonmangel
EP3493828C0 (en) COMPOSITIONS FOR ADMINISTRATION OF APOA1 AND DOSAGES